Cannabis Rescheduling: Page 2

Trulieve Approved to Uplist on New York Stock Exchange

The company announced its subordinate voting shares are expected to begin trading under the ticker ‘TRLV’ on June 10 on the NYSE.

5 ‘Aggrieved Persons’ Sue Trump, DOJ Over Cannabis Rescheduling Order

A substance abuse recovery clinic, two doctors, a victims’ advocacy organization and a pharmaceutical company claim the order was unlawful.

7 House Democrats Demand IRS, Treasury Provide 280E Cannabis Guidance

The U.S. representatives sent a letter urging ‘clear, timely guidance’ for state-licensed medical businesses following the DOJ’s rescheduling order.

ATACH Assembles Legal Team to Defend Schedule III, Defeat Prohibitionist Opponents

The American Trade Association for Cannabis and Hemp filed a formal notice to participate in the DEA hearing and retained Shane Pennington of Blank Rome.

Jushi Applies for DEA Registration of State-Licensed Medical Cannabis Operations

The multistate operator announced it is seeking expedited registration approval from the DEA under the federal Schedule III framework.

3 States Challenge Trump DOJ’s Schedule III Cannabis Rule

Nebraska, Indiana and Louisiana filed a petition for review in federal court, arguing that immediately rescheduling medical cannabis violates administrative procedures.

White House’s ‘New Legal Authority’ for Hemp THC Products Leads CBT’s Top Stories in May

The Trump administration’s drug control strategy indicated enforcement of intoxicating hemp products that have largely gone unregulated.

Cresco Labs Marks Historic Step Forward With Medical Cannabis Facility DEA Registrations

The registrations are for the company’s dispensary, cultivation and processing operations.

SAFE Banking Act Nowhere to Be Found in Wake of Schedule III Cannabis Order

The new federal posture toward loosening restrictions on cannabis does not appear to have increased congressional appetite for industry banking reform.

Cannabis Business Leans on Schedule III Listing, Asks US Tax Court to Recognize 280E Refunds for Prior Years

The IRS can’t dispute that medical cannabis falls outside the meaning of Schedule I or II ‘without contradicting the president, the acting attorney general and HHS,’ the company says.

Former Federal Prosecutor, Former IRS Lawyer Warn Cannabis Industry About Jumping on DEA Registration Bandwagon

The takeaway? Consult with experienced lawyers and tax professionals and consider the risks, as the landscape continues to shift.

DEA Says Red-Flag Question on Schedule III Application ‘Not Intended … as a Categorical Barrier’

The DEA says the Schedule III registration-form question asking cannabis businesses to admit to dealing in controlled substances without DEA authorization is designed ‘to support a complete and fair evaluation of each application,’ and ‘the broader registration process is designed to evaluate applicants based on their current ability to operate within the federal framework.’

Previous Page

Page 2 of 19

Next Page